Acorn Financial Advisory Services Inc. ADV Sells 89 Shares of Johnson & Johnson (NYSE:JNJ)

Acorn Financial Advisory Services Inc. ADV decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,884 shares of the company’s stock after selling 89 shares during the quarter. Acorn Financial Advisory Services Inc. ADV’s holdings in Johnson & Johnson were worth $611,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Hibernia Wealth Partners LLC purchased a new position in Johnson & Johnson during the 3rd quarter valued at approximately $27,000. FNY Investment Advisers LLC purchased a new position in Johnson & Johnson during the 3rd quarter valued at approximately $37,000. Tower View Wealth Management LLC grew its holdings in Johnson & Johnson by 183.3% during the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 165 shares in the last quarter. Creative Capital Management Investments LLC grew its holdings in Johnson & Johnson by 43.0% during the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after buying an additional 86 shares in the last quarter. Finally, VitalStone Financial LLC purchased a new position in Johnson & Johnson during the 2nd quarter valued at approximately $48,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Trading Up 1.4 %

JNJ opened at $157.96 on Thursday. The firm has a market cap of $380.65 billion, a price-to-earnings ratio of 11.44, a PEG ratio of 2.62 and a beta of 0.53. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a 12 month low of $144.95 and a 12 month high of $175.97. The stock has a fifty day moving average price of $158.76 and a 200-day moving average price of $156.69.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The firm had revenue of $21.40 billion for the quarter, compared to the consensus estimate of $21.02 billion. During the same period in the previous year, the business earned $2.35 EPS. The firm’s revenue for the quarter was down 9.7% on a year-over-year basis. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th were paid a dividend of $1.19 per share. The ex-dividend date of this dividend was Friday, February 16th. This represents a $4.76 annualized dividend and a yield of 3.01%. Johnson & Johnson’s dividend payout ratio (DPR) is 34.47%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on JNJ. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, March 13th. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 28th. Wells Fargo & Company cut Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. UBS Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $167.00 to $180.00 in a report on Friday, December 1st. Finally, Morgan Stanley dropped their price objective on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. Seven analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $177.31.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.